Kenji Nozaki, Dai Maruyama, Akiko Miyagi Maeshima, Kinuko Tajima, Jun Itami, Takafumi Shichijo, Sayako Yuda, Tomotaka Suzuki, Kosuke Toyoda, Nobuhiko Yamauchi, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Yukio Kobayashi, Hirokazu Taniguchi, Koji Izutsu, Kensei Tobinai
OBJECTIVES: This study aimed to evaluate the outcomes of local radiotherapy (LRT) in patients with histologic transformation (HT) following rituximab-containing chemotherapy. METHODS: We retrospectively analysed 92 patients with biopsy-confirmed HT undergoing rituximab-containing chemotherapy at our institution between 2003 and 2015. RESULTS: Of the 36 patients with limited-stage disease at diagnosis of HT, 29 (78%) received LRT. The estimated 5-year progression-free survival (PFS) rate was significantly better in patients who underwent LRT than in those who did not (93% and 42%, respectively; P < 0...
October 24, 2020: European Journal of Haematology
Yuichiro Uchida, Makoto Yoshimitsu, Miho Hachiman, Shuichi Kusano, Naosuke Arima, Kodai Shima, Maiko Hayashida, Yuhei Kamada, Daisuke Nakamura, Akihiko Arai, Yuetsu Tanaka, Hiromitsu Hara, Kenji Ishitsuka
OBJECTIVES: Adult T-cell leukemia/lymphoma (ATL) is an intractable T-cell malignancy caused by long-term infection with human T-cell leukemia virus type-1 (HTLV-1). While ATL pathogenesis has been associated with HTLV-1-derived oncogenic proteins, including Tax and HBZ, the contribution of genomic aberrations remains poorly defined. METHODS: To elucidate the genomic basis of ATL, whole exome sequencing was performed on cells from 47 patients with aggressive ATL...
October 24, 2020: European Journal of Haematology
Ayoma D Attygalle, Dorte Wren, Rachel Dobson, Katherine M Vroobel, Bhupinder Sharma, Simon O'Connor, Andrew C Wotherspoon, Ming-Qing Du, David Cunningham
Angioimmunoblastic T-cell lymphoma (AITL) is one of the commonest subtypes of peripheral T-cell lymphoma (PTCL) world-wide and the most common non-cutaneous PTCL in Western Europe. Despite aggressive chemotherapy +/- consolidation autologous stem cell transplant relapse occurs in >50% of cases which is either treated aggressively with high dose chemotherapy followed by allogeneic transplant or with therapy aimed at producing prolonged disease control.1 Biopsy of relapsed disease is essential as a subset may be complicated by a B-cell (often EBV+) lymphoproliferation...
October 24, 2020: Histopathology
Massimo Mascolo, Antonio Travaglino, Silvia Varricchio, Daniela Russo, Elena Sabattini, Claudio Agostinelli, Clara Bertuzzi, Antonello Baldo, Alessandro Pileri, Marco Picardi, Fabrizio Pane, Stefania Staibano
Mycosis fungoides (MF) represents the most common type of cutaneous lymphoma. In the majority of patients, the disease has a slow evolution and a protracted course; however, a subset of patients shows poor oncologic outcomes. Unfortunately, there are no reliable prognostic markers for MF, and the currently available treatments are only effective in a minority of patients. This study aimed to evaluate the expression and clinical significance of PARP-1 and CAF-1/p60 in MF. Sixty-four MF representatives of the different stages of disease were assessed by immunohistochemistry for PARP-1 and CAF-1/p60...
October 24, 2020: Virchows Archiv: An International Journal of Pathology
İlker EyÜboĞlu, İsmet MİraÇ Çakir, Serdar Aslan, Ahmet Sari
PURPOSE: To evaluate diagnostic efficacy of the apparent diffusion coefficient measurements from tumor (ADCt) and tumor circumference hyperintensities (ADCtch) in different types of malignant intra-axial brain tumors. MATERIALS AND METHODS: Between April 2013 - June 2017, 125 patients (52 females (41.6%) and 73 males (58.4%); mean age, 53 years; age range, 14-81 years), who underwent diffusion-weighted imaging (DWI) with intracranial mass, were retrospectively evaluated...
October 24, 2020: Turkish Journal of Medical Sciences
Bruna Melhoranse Gouveia, Jillian Wells, Jennifer Kim, Helena Collgros, Pascale Guitera, Caterina Longo, Pablo Fernandez-Penas
BACKGROUND: Reflectance confocal microscopy (RCM) is a useful tool for many skin cancers, allowing non-invasive evaluation over time and identifying areas of active disease. Its role to follow-up mycosis fungoides (MF) patients has not yet been evaluated. OBJECTIVE: To assess the level of agreement between RCM and histopathology and to develop a RCM checklist that could help monitoring MF patients. METHOD: Prospective study in a cutaneous lymphoma clinic of a tertiary hospital in Australia...
October 24, 2020: Skin Research and Technology
Jisun Jeong, Sun Woong Kim, Duk Hyun Sung
OBJECTIVES: Neurolymphomatosis (NL) is a disease characterized by the infiltration of malignant lymphocytes into the peripheral nervous system. We report clinical features, radiographic findings, modes of treatment, and outcomes of patients with NL. METHODS: We retrospectively investigated patients with NL. We extracted data, including clinical features, magnetic resolution imaging (MRI), 18 F-fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scans, cerebrospinal fluid cytology findings, the results of electrodiagnostic studies, as well as patient treatments and outcomes...
October 23, 2020: Journal of Neurology
Paul Blanc-Durand, Simon Jégou, Salim Kanoun, Alina Berriolo-Riedinger, Caroline Bodet-Milin, Françoise Kraeber-Bodéré, Thomas Carlier, Steven Le Gouill, René-Olivier Casasnovas, Michel Meignan, Emmanuel Itti
PURPOSE: Lymphoma lesion detection and segmentation on whole-body FDG-PET/CT are a challenging task because of the diversity of involved nodes, organs or physiological uptakes. We sought to investigate the performances of a three-dimensional (3D) convolutional neural network (CNN) to automatically segment total metabolic tumour volume (TMTV) in large datasets of patients with diffuse large B cell lymphoma (DLBCL). METHODS: The dataset contained pre-therapy FDG-PET/CT from 733 DLBCL patients of 2 prospective LYmphoma Study Association (LYSA) trials...
October 24, 2020: European Journal of Nuclear Medicine and Molecular Imaging
Shintaro Yamanaka, Masao Miyagawa, Yoshifumi Sugawara, Shinji Hasebe, Tomomi Fujii, Kazuto Takeuchi, Keiko Tanaka, Yoshihiro Yakushijin
BACKGROUND: Positron Emission Tomography-Computed Tomography (PET-CT) has been changing diagnostic and therapeutic strategies for patients with cancers, and several PET-CT-related prognostic factors have been reported. We have focused on metabolic tumor volumes (MTVs) over the whole body and in specific organs using 18F-PET-CT imaging, and have compared clinical data to know the prognosis of patients with diffuse large B cell lymphoma (DLBCL). PATIENTS AND METHODS: From January 2006 to December 2016, patients who were newly diagnosed for de novo DLBCL and who received 18F-FDG PET-CT scans for disease staging at Ehime University Hospital were reviewed...
October 23, 2020: International Journal of Clinical Oncology
(no author information available yet)
An excess of exhausted T cells may explain why some patients with large B-cell lymphoma do not benefit from chimeric antigen receptor (CAR) T cells, a recent study concludes. The research also shows that patients with monocyte-like cells in their infusions are more likely to develop severe neurologic side effects. The study suggests measures to increase the effectiveness and safety of CAR T-cell products.
October 23, 2020: Cancer Discovery
Sriman Swarup, Jonathan Kopel, Kyaw Zin Thein, Kaiser Tarafdar, Khatrina Swarup, Seshadri Thirumala, Donald P Quick
In this case report of a patient with angioimmunoblastic T-cell lymphoma (AITL), we describe the occurrence of three sequential complications that have been reported uncommonly in this disease subtype. Firstly, the patient developed hypercalcemia due to elevated 1,25-didydroxyvitamin D. Although hypercalcemia in AITL is not rare (1-2% incidence), this case was unusual in that the complication developed when disease appeared stable and symptomatically, he was doing well otherwise. Hypercalcemia surprisingly resolved a few months later at a time when his disease appeared to be progressing...
September 3, 2020: American Journal of the Medical Sciences
Mu-Chen Zhang, Ying Fang, Li Wang, Shu Cheng, Di Fu, Yang He, Yan Zhao, Chao-Fu Wang, Xu-Feng Jiang, Qi Song, Peng-Peng Xu, Wei-Li Zhao
BACKGROUND: Elderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma activities and can be applied to treat DLBCL. This study aimed to evaluate efficacy and safety of oral HDACI tucidinostat (formerly known as chidamide) plus R-CHOP (CR-CHOP) in elderly patients with newly diagnosed DLBCL (International Prognostic Index ≥ 2). RESULTS: Among 49 patients, the complete response rate was 86%, with overall response rate achieving 94%...
October 23, 2020: Clinical Epigenetics
Houkun Li, Limin He, Yuan Tuo, Yansheng Huang, Bing Qian
BACKGROUND: Circular RNAs (circRNAs) have emerged as a novel category of non-coding RNA, which exhibit a pivotal effect on regulating gene expression and biological functions, yet how circRNAs function in osteosarcoma (OSA) still demands further investigation. This study aimed at probing into the function of hsa_circ_0000282 in OSA. METHODS: The expressions of circ_0000282 and miR-192 in OSA tissues and cell lines were examined by quantitative real-time polymerase chain reaction (qRT-PCR), and the correlation between the expression level of circ_0000282 and clinicopathological features of OSA patients was analyzed...
October 23, 2020: BMC Cancer
Daria Gaut, Kevin Tang, Myung Shin Sim, Tuyen Duong, Patricia Young, Joshua Sasine
Little is known about the benefits and risks of myeloid growth factor administration following Chimeric Antigen Receptor (CAR) T-cell therapy for Diffuse Large B-cell Lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who received CAR T-cell therapy with axicabtagene ciloleucel. Filgrastim was administered by physician discretion to 7 patients (31.8%), and the median duration of neutropenia following lymphodepleting therapy was significantly shorter for those patients who received filgrastim (5 days vs 15 days, p = 0...
October 22, 2020: International Journal of Cancer. Journal International du Cancer
Wenhai Huang, Shu Wang, Zhimin Zhang, Chixiao Zhang, Shenxin Zeng, Meihao Liang, Zhengrong Shen, Xingguo Liu
Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec kinases family and is essential for B cell receptor (BCR) mediated signaling. BTK inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. Here we disclose a potent, selective, and covalent BTK inhibitor, HZ-A-005, currently in preclinical development. HZ-A-005 demonstrated dose-dependent activity in two xenograft models of lymphoma in vivo. It showed highly favourable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical studies...
October 13, 2020: Bioorganic Chemistry
Wei-Qiong Zuo, Rong Hu, Wan-Li Wang, Yong-Xia Zhu, Ying Xu, Luo-Ting Yu, Zhi-Hao Liu, Ning-Yu Wang
PI3Kδ has proved to be an effective target for anti-lymphoma drugs. However, the application of current approved PI3Kδ inhibitors has been greatly limited due to their specific immune-mediated toxicity and increased risk of infection, it is necessary to develop more PI3Kδ inhibitors with new scaffold. In this study, SAR study with respect to piperazinone-containing purine derivatives led to the discovery of a potent and selective PI3Kδ inhibitor, 4-(cyclobutanecarbonyl)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one (WNY1613)...
October 8, 2020: Bioorganic Chemistry
Fei Lu, Yanan Zhao, Yihua Pang, Min Ji, Yanping Sun, Hongchun Wang, Jie Zou, Yan Wang, Guosheng Li, Tao Sun, Jingxin Li, Daoxin Ma, Jingjing Ye, Chunyan Ji
The NLRP3 inflammasome plays a pro-tumorigenic role in various malignancies. However, its potential role in lymphomagenesis remains unclear. In this study, we identified an immunosuppressive state in patients with diffuse large B cell lymphoma (DLBCL), which was characterized by markedly elevated interleukin (IL)-18 levels in lymphoma tissues and positive correlation with programmed death ligand 1 (PD-L1) expression. Furthermore, NLRP3 inflammasome activation in DLBCL cell lines upregulated PD-L1 and reduced the proportion of cytotoxic T cells...
October 19, 2020: Cancer Letters
Huang-He Yu, Yi-Xing Qiu, Bin Li, Cai-Yun Peng, Rong Zeng, Wei Wang
ETHNOPHARMACOLOGICAL RELEVANCE: Kadsura heteroclita stem (KHS) is a well-known hepatoprotective Tujia ethnomedicine (folk named Xuetong), has long been used for the prevention and treatment of hepatitis and liver diseases. AIM OF THE STUDY: To explore the protective effects of KHS against carbon tetrachloride (CCl4 )-induced liver injury and the underlying mechanism, particularly antioxidative, anti-inflammatory, and anti-apoptotic potentials. MATERIALS AND METHODS: The acute toxicity of KHS was measured by the method of maximum tolerated dose (MTD)...
October 19, 2020: Journal of Ethnopharmacology
Jennifer K Lue, Owen A O'Connor
The integration of rituximab (R) into cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) by Coiffier and colleagues was the first, and last, successful modification of this backbone regimen, which has endured now for almost 20 years. Countless attempts to redefine R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL) have migrated from a focus on dose-intense and dose-dense regimens, to the use of maintenance therapies, and most recently the addition of novel agents. To date, none have changed the basic formula...
November 2020: Lancet Haematology
Jorge J Castillo, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Marie José Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, M Lia Palomba, Dipti Talaulikar, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis
Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined criteria for diagnosis, initiation of therapy, and response, which was established by consensus panels at previous International Workshops for Waldenström Macroglobulinaemia (IWWM). The treatment options for Waldenström macroglobulinaemia continued to be researched after the publication of the eighth IWWM consensus recommendations in 2016, and at the tenth IWWM in New York, USA (October, 2018) an international consensus panel was formed to update treatment recommendations...
November 2020: Lancet Haematology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"